Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Becton Dickinson and Co C.BDX


Primary Symbol: BDX

Healthcare Medical Devices
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.


NYSE:BDX - Post by User

Becton Dickinson and Co
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(273)
•••
Post by partystockeron Oct 28, 2021 1:02pm
55 Views
Post# 34059560

$NCLR snags new CEO

$NCLR snags new CEO

Basin Uranium Corp. $NCLR just announced the appointment of Mike Blady as CEO. He has: 


  • A great track record of raising capital (in excess of $100M in the course of his 12 year career) 

  • lots of experience in all facets of building, growing and operating a public company. Blady also sits on the boards of several publicly traded companies. 


$NCLR is the new ticker for the recently renamed Black Shield Metals. I like that the name change gives more specificity to the company's operations. 


This will provide better SEO as well, and bring $NCLR in front of more investors looking to gain exposure to uranium junior mining. 


$NCLR.CN is up ~7% today at $.75, looking forward to seeing how the new direction for the company plays out. 


https://ceo.ca/@thenewswire/basin-uranium-announces-new-chief-executive-officer

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities